Karyopharm Therapeutics Inc. Announced earnings guidance for the year 2023. Based on its current operating plans, Karyopharm is updating its guidance for full year 2023: Total revenue to be in the range of $145 million to $160 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9691 USD | +2.20% | -7.70% | +12.03% |
May. 08 | Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Reports Q1 Revenue $33.1M, vs. Street Est of $34.5M | MT |
May. 08 | Transcript : Karyopharm Therapeutics Inc., Q1 2024 Earnings Call, May 08, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.03% | 121M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- KPTI Stock
- News Karyopharm Therapeutics Inc.
- Karyopharm Therapeutics Inc. Announces Earnings Guidance for the Year 2023